Navigation Links
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine

Following FDA Approval, Company Announces $7,800 Wholesale Price for

Lifesaving Drug

LOS ANGELES, Jan. 21 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS. Immediately following FDA approval of the drug, which Tibotec will sell under the brand name Intelence, Reuters reported that the drug's wholesale cost will be $5.45 per tablet. At the approved dose of two tablets twice per day, a 30-day supply would be $654-or close to $8,000 per patient, per year (PPY) wholesale cost.

"We commend Tibotec for the development of this promising new HIV/AIDS drug, but strongly urge them to immediately reconsider and price this life- saving AIDS medicine more fairly," said Michael Weinstein, AIDS Healthcare Foundation President. "As with many AIDS drugs before it, the cost of Intelence will simply be out of the price range for most AIDS patients and threatens to further stress Medicaid and AIDS Drug Assistance Programs nationwide. Just last week, Governor Arnold Schwarzenegger announced plans to cut $7 million dollars from California's ADAP, a program that helps low-income Californians living with HIV/AIDS access such lifesaving drugs. AIDS drugs are priced at the maximum the market will bear, regardless of production costs. It appears Tibotec is once again following suit with the steep price of its newest AIDS drug."

Tibotec drew earlier criticism from AIDS advocates back in June 2006 after it received FDA approval for its Protease Inhibitor, Prezista (darunavir, or TMC 114) and began marketing that HIV/AIDS drug at a price well above other drugs in its class -- close to $10,000 per patient per year. According to Tibotec's own website at the time, Prezista had been found to be, " ... highly-active in vitro against HIV with Protease Inhibitor resistance mutations...," and was found to be particularly effective as part of a second or third line 'salvage' therapy used in combination with Roche and Trimeris' drug, Fuzeon ($20,000 per patient per year) and Abbott's Norvir ($7,800). Taken together -- as these medications are usually prescribed as part of a lifesaving AIDS drug cocktail or regimen -- the cost for these drugs for one HIV/AIDS patient runs between $35,000 and $40,000 per patient per year.

In clinical trials, Tibotec's latest drug, Intelence, has been found to be effective for many HIV-infected patients who are NNRTI-resistant and whose infections are not responding to currently available medications. It is widely expected to be prescribed and used in conjunction with other AIDS drugs as part of salvage regimens for patients whose previous drug combinations have failed them.

"As many states and the federal government also face significant budget constraints and are drastically cutting budgets and services, we question Tibotec's judgment and timing in pricing this latest AIDS drug so high," added AHF's Weinstein. "When Governor Schwarzenegger proposed eliminating $7 million in drugs for co-morbidities and opportunistic infections from the ADAP formulary last week, AIDS Healthcare Foundation said that instead of cutting any drugs from the ADAP formulary, the Governor and state lawmakers should instead reduce reimbursements to drug companies and try to purchase drugs for ADAP and other crucial state programs at federal pricing levels such as those that the Department of Veterans Affairs has successfully negotiated with the industry. We vow to work in Sacramento and in Washington to ensure that ADAP and other similar government programs do not continue to become glorified corporate welfare programs that boost the coffers and bottom lines of drug companies while the state and the nation's voiceless, poor and disabled are being forced to endure drastic cuts to the very programs that help keep them alive."

About AHF

AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare, research, prevention and education provider. In California, AHF operates the largest non-government HIV testing program, which conducts more than 15,000 HIV tests annually. AHF currently provides medical care and/or services to more than 62,000 individuals in 20 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at

SOURCE AIDS Healthcare Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kmart Lowers Flu Shot Price to $10
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):